RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
RAPT Therapeutics (Nasdaq: RAPT) will present a company overview at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RAPT Therapeutics (Nasdaq: RAPT) will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference. Brian Wong, M.D., Ph.D., President and CEO, is scheduled to present on Wednesday, January 14, 2026 at 2:15 p.m. PT. Investors can access a live webcast and an archived recording via the company’s investor website.
This presentation is a corporate overview at a major industry conference and does not include new financial guidance or clinical readouts in the announcement.
Details
News Market Reaction – RAPT
On Jan 8, the first trading day after this news, RAPT closed 3.76% below the previous close.
Data tracked by StockTitan Argus for the Jan 8 session.
Key Figures
- Conference edition
- 44th
- 44th Annual J.P. Morgan Healthcare Conference
- Presentation date
- January 14, 2026
- Scheduled company overview presentation
- Presentation time
- 2:15 p.m. Pacific Time
- Scheduled conference presentation slot
Historical Context
-
Q3 2025 results plus IND clearance and cash runway extension to mid-2028.
-
Announcement of participation in three November 2025 investor conferences.
-
Initiation of prestIgE Phase 2b ozureprubart trial in food allergy.
-
Pricing of public offering of 8,333,334 shares at $30.00 per share.
-
Announcement of proposed underwritten public offering of common stock.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 44thAnnual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific Time.
To access the live webcast or subsequent archived recording of the presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
About RAPT Therapeutics, Inc.
RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.